Company intelligence / Profile preview

Sermens

Ownership: Private
Development stage: Other

Overview

Sermonix Pharmaceuticals develops and commercializes female-specific oncology products. Its lead asset, lasofoxifene—a selective estrogen receptor modulator—is being evaluated against fulvestrant in postmenopausal women and premenopausal women with ovarian suppression who have locally advanced/metastatic ER+/HER2-, ESR mutation-positive breast cancer that has progressed following aromatase inhibitor plus CDK4/6 inhibitor therapy. The ELAINE study focuses on progression-free survival as its primary endpoint.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sermens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sermens.

Explore the full profile